Jaume Capdevila, MD, PhD

Efficacy and Safety of the DLL3/CD3 T-Cell Engager Obrixtamig in Patients With Extrapulmonary Neuroendocrine Carcinomas With High or Low DLL3 Expression: Results From an Ongoing Phase 1 Trial

June 20th 2025

Jaume Capdevila, MD, PhD, presents results from a phase 1 study showing that obrixtamig monotherapy achieves a 40% response rate and durable disease control with manageable safety in patients with extrapulmonary neuroendocrine carcinoma, particularly those with high DLL3 expression.